- Critical care
- Infectious Diseases
- Mental Health
- Metabolic and Endocrine
- Musculoskeletal Health
- Neuroprogressive and Dementia
- Oral and Dental
- Primary Care
- Regenerative Medicine
- Reproductive Health and Childbirth
The Cancer Network supports a wide range of clinical studies which are helping to progress cancer care in Scotland and beyond and all Scottish research ongoing within the network is registered with the National Institute of Health Research (NIHR). The cancer clinical trial portfolio is very dynamic and is frequently changing as studies open and close to recruitment. Across Scotland there are a wide range of clinical trials happening in different disease sites. Information on trials happening in the UK can be found on the UK Clinical Trials Gateway and the CRUK websites. For specific information on trials happening in Scotland please contact your cancer professional or your local cancer research network.
To highlight the clinical trials happening in Scotland the cancer research network will feature current trials happening during the different cancer awareness months that happen throughout the year.
May: Bladder Cancer Awareness Month and Skin/Sun Awareness Month
Bladder cancer begins in the lining of the bladder. The bladder is part of the urinary system, which filters waste products out of your blood and makes urine. Around 10,300 people are diagnosed with bladder cancer every year in the UK. Generally more men than women get bladder cancer and it is usually more common in those over 60 years of age.
For more information on bladder cancer please visit the CRUK website
ATLANTIS is an adaptive multi-arm phase II trial of maintenance targeted therapy after chemotherapy in metastatic urothelial cancer.
In simpler terms; it is testing different treatments for different subtypes of urinary tract cancer in patients that have already had chemotherapy. It is for people whose cancer has grown into surrounding tissues or spread elsewhere in the body (advanced cancer). The trial hopes to show that these treatments can stop the cancer growing back again after chemotherapy and prolong life expectancy, and also looks at the side effects of using these additional treatments.
For further information please click here
Skin cancer includes basal cell skin cancer, squamous cell skin cancers, and other rarer types. These cancers occur in the epidermis layer of the skin. Melanoma is the 5th most common cancer in the UK and is the most aggressive form of the disease. It develops from damage to the skin cells called melanocytes which are in the deeper layers of the epidermis. Skin cancer tends to develop most often on skin that's been exposed to the sun. It is important that you check your skin regularly and see a doctor if any changes occur.
For more information on skin cancers please visit the CRUK website
DANTE is a new randomised phase III trial to evaluate the Duration of ANti-PD1 monoclonal antibody Treatment in patients with metastatic melanoma. It is for patients with advanced melanoma that has spread to the lymph nodes.
In simpler terms; it is a form of immunotherapy where treatment is given to switch on the body’s own defence mechanism to fight the cancer cells. Cancer cells can contain high levels of protein which stop the T cells from fighting infection. Checkpoint inhibitors such as Nivolumab and Pembrolizumab can switch off these proteins in order to stimulate the T cells into fighting the cancer cells. The objectives of the trial are to see if it stops the progression of the disease, assess the tumour’s response to the treatment and look at overall survival rates. The trial will be recruiting soon in Aberdeen, Dundee, Edinburgh and Glasgow.
Follow link for more information on Immunotherapy.